Immunohistochemical characterization of mullerian mucinous borderline tumors: possible histogenetic link with serous borderline tumors and low-grade endometrioid tumors

Yasunaga, Masafumi; Ohishi, Yoshihiro; Oda, Yoshinao; Misumi, Munechika; Iwasa, Atsuko; Kurihara, Shuichi; Nishimura, Isao; Okuma, Emi; Kobayashi, Hiroaki; Wake, Norio; Tsuneyoshi, Masazumi

doi:10.1016/j.humpath.2008.12.006

Cited by 41 publications

(40 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SPT24 shows greater sensitivity in detecting more pulmonary tumors of all histologic subtypes at the expense of its specificity, contributing to a few reported expressions of TTF1 in breast, colon, and gynecologic tumors and colon. [123][124][125][126][127][128][129][130][131][132] Thus, 8G7G3/1 might be a better choice to differentiate primary from metastatic carcinomas. In recent years, many organspecific markers have been established.…”

Section: Application Of Ihc For the Differential Diagnosis Of Sarcomamentioning

confidence: 99%

Utility of Immunohistochemistry in the Diagnosis of Pleuropulmonary and Mediastinal Cancers: A Review and Update

Zhang

Deng

Cagle

2014

Archives of Pathology &Amp; Laboratory Medicine

View full text Add to dashboard Cite

Context.-Immunohistochemistry has become an indispensable ancillary tool for the accurate classification of pleuropulmonary and mediastinal neoplasms necessary for therapeutic decisions and predicting prognostic outcome in the era of personalized medicine. Diagnostic accuracy has significantly improved because of the continuous discoveries of tumor-associated biomarkers and the development of effective immunohistochemical panels.Objective.-To increase the accuracy of diagnosis and classify pleuropulmonary neoplasms through immunohistochemistry.Data Sources.-Literature review, authors' research data, and personal practice experience.Conclusions.-This review article has shown that appropriately selecting immunohistochemical panels enables pathologists to effectively diagnose most primary pleuropulmonary neoplasms and differentiate primary lung tumors from a variety of metastatic tumors to the lung. The discovery of new mutation-specific antibodies identifying a subset of specific gene-arranged lung tumors provides a promising alternative and cost-effective approach to molecular testing. Knowing the utilities and pitfalls of each tumor-associated biomarker is essential to avoiding potential diagnostic errors.

show abstract

Section: Application Of Ihc For the Differential Diagnosis Of Sarcomamentioning

confidence: 99%

Utility of Immunohistochemistry in the Diagnosis of Pleuropulmonary and Mediastinal Cancers: A Review and Update

Zhang

Deng

Cagle

2014

Archives of Pathology &Amp; Laboratory Medicine

View full text Add to dashboard Cite

show abstract

“…Recent studies may change our view of ovarian/ mullerian mucinous borderline tumors (28,38). Fukunaga and Ushigome (28) suggested the possibility that endometriosis with mucinous metaplasia and epithelial hyperplasia might contribute to the histogenesis of mullerian mucinous borderline tumors (28).…”

Section: Endometriosis and Ovarian Cancer: Natural History And Pathogmentioning

confidence: 99%

Endometriosis and Ovarian Cancer

Wei

William

Bulun

2011

International Journal of Gynecological Pathology

151

View full text Add to dashboard Cite

Summary Endometriosis is a chronic disease that affects millions of reproductive-age women. Despite the destructive and invasive nature of endometrioses, most cases are perpetually benign or eventually regress; however, atypical endometriosis is a precursor lesion and can lead to certain types of ovarian cancer. Endometriosis induced inflammation and auto- and paracrine production of sex steroid hormones contribute to ovarian tumorigenesis. These changes provide microenvironment necessary to accumulate enough genetic alterations for endometriosis associated malignant transformation. It takes years for endometriosis to undergo the pathophysiological progression that begins with atypical epithelial proliferation (atypical endometriosis and metaplasia), and then is followed by the formation of well-defined borderline tumors, and finally culminates in fully malignant ovarian cancer. This study is a review of the natural history of endometriosis and the role of microenvironments that favor the accumulation of genetic alterations and endometriosis-associated ovarian cancer progression.

show abstract

“…However, there are distinct immunohistochemical differences [55][56][57]. Both neoplastic types are typically diffusely positive with CK7, although intestinal type neoplasms may be only focally positive or even negative on rare occasions.…”

Section: Immunohistochemistry Of Mucinous Borderline Tumoursmentioning

confidence: 99%

The pathology of and controversial aspects of ovarian borderline tumours

McCluggage

2010

Current Opinion in Oncology

View full text Add to dashboard Cite

Ovarian borderline tumours have an excellent prognosis, although a small percentage is associated with the development of progressive disease. It has been suggested that the term borderline tumour should be abandoned but it is argued that this terminology should be retained for both serous and mucinous neoplasms because of the risk of extraovarian implants in serous borderline tumours and the large size and heterogeneity of mucinous borderline tumours which may result in an invasive focus being undetected by the pathologist.

show abstract

Immunohistochemical characterization of mullerian mucinous borderline tumors: possible histogenetic link with serous borderline tumors and low-grade endometrioid tumors

Cited by 41 publications

References 34 publications

Utility of Immunohistochemistry in the Diagnosis of Pleuropulmonary and Mediastinal Cancers: A Review and Update

Utility of Immunohistochemistry in the Diagnosis of Pleuropulmonary and Mediastinal Cancers: A Review and Update

Endometriosis and Ovarian Cancer

The pathology of and controversial aspects of ovarian borderline tumours

Contact Info

Product

Resources

About